1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Prostate cancer

Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen

Technology appraisal guidance [TA259] Published date: 27 June 2012 Last updated: 27 July 2016

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...

Information for the public


  • Abiraterone for metastatic prostate cancer after treatment to reduce testosterone and docetaxel chemotherapy 27 June 2012   PDF 181.36 KB
NICE
  • About NICE
  • Into practice
  • News
  • Contact us
  • Leave feedback
  • Jobs
  • Newsletters and alerts
  • Blog
  • Twitter
  • YouTube
  •   Facebook
  • LinkedIn

Explore

  • Guidance
  • Pathways
  • Standards and indicators
  • Savings and productivity
  • Evidence search
  • BNF
  • BNFC
  • Clinical knowledge summaries
  • Journals and databases

Reusing our content

  • Reuse information
  • NICE UK Open Content Licence

Guidance app

  • Android
  • iOS

Get involved

  • Register as a stakeholder
  • Citizens council
  • Consultations
  • Fellows and scholars
  • Join a committee
  • Meetings in public
  • Student champions
  • Tenders
  • Public involvement
  • Accessibility
  • Freedom of information
  • Syndication services
  • Glossary
  • Terms and conditions

Copyright © 2017 National Institute for Health and Care Excellence. All rights reserved.